Clinical Trials Logo

Hyponatremia clinical trials

View clinical trials related to Hyponatremia.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04588207 Terminated - Hyponatremia Clinical Trials

Urea for Chronic Hyponatremia

Start date: December 28, 2021
Phase: Phase 2
Study type: Interventional

This study is examining how a dietary supplement called urea can be used to treat low blood sodium level. Low blood sodium level is a common problem and some studies show that many patients with low blood sodium level suffer from brain fog and/or loss of balance. Unfortunately, it is unknown at this point what the best treatment is for low blood sodium level. With this pilot research study, the investigators are hoping to learn more about whether urea is safe to take, whether patients can tolerate taking urea for several weeks, whether urea increases blood sodium level, and whether urea can help prevent the brain fog and/or loss of balance that some patients with low blood sodium level suffer from. The information obtained with this study is intended to be used to design a larger study in the future to get a definite answer whether urea is beneficial for patients with low blood sodium level.

NCT ID: NCT04020926 Terminated - Hyponatremia Clinical Trials

Impact of Hyponatremia on Muscle Strength, Gait and Cognitive Function

Start date: October 1, 2019
Phase:
Study type: Observational

In this study patients with hyponatremia, defined as a serum sodium < 126 mmol/L on admission to the hospital will be tested for muscular power by use of a hand grip dynamometer, for cognitive function by use of the Montreal-Cognitive-Assessment and gait stability by use of the Tinetti test. The tests will be performed on admission as well es after correction of hyponatremia.

NCT ID: NCT03703713 Terminated - Hyponatremia Clinical Trials

Colloid Osmotic Pressure and Osmolality in Hyponatremia

Start date: October 9, 2018
Phase:
Study type: Observational

Hyponatremia (serum sodium of less than 135 mmol/L)is a very common electrolyte disorder. The reasons for the disorder varies as well as if it is acute or chronic. In this study we wish to follow changes in colloid osmotic pressure and osmolality during the initial treatment hours. We also wish to use mass balance for the calculation of body compartments and to detect fluid translocation between these.

NCT ID: NCT02959411 Terminated - Heart Failure Clinical Trials

Tolvaptan for Advanced or Refractory Heart Failure

Start date: October 2016
Phase: Phase 4
Study type: Interventional

This study will clarify the clinical usefulness of Tolvaptan therapy in patients with complicated acute decompensated heart failure and hyponatremia (low blood sodium).

NCT ID: NCT02545114 Terminated - Hyponatremia Clinical Trials

Tolvaptan for Patients With Acute Neurological Injuries

Start date: August 2015
Phase: N/A
Study type: Interventional

Hyponatremia occurs frequently in patients with acute brain injury in the days to weeks following injury, and may contribute to adverse outcome. In addition, hyponatremia can aggravate neurologic dysfunction, complicate neurological assessments, and contribute to neurologic symptoms such as gait dysfunction that can impair efforts at mobilization and rehabilitation. Strict normonatremia (serum Na levels between 135 and 145 meq/dl) is the goal in most patients with acute brain injury. SIADH is the most frequent cause of hyponatremia in patients with neurological injury; however, treatment with fluid restriction is often difficult or contra-indicated, for example in patients with subarachnoid hemorrhage (SAH) where intravascular hypovolemia can trigger vasospasms. The aim of this project is to test Tolvaptan, an ADH antagonist, as a treatment in selected patients with acute brain injury who have developed SIADH.

NCT ID: NCT02352285 Terminated - Clinical trials for Heart Failure With Hyponatremia

Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure

AQUATIC
Start date: December 2012
Phase: Phase 4
Study type: Interventional

The objective is to evaluate the efficacy and safety on the tolvaptan for increasing serum Na levels in patients with worsening heart failure and hyponatremia.

NCT ID: NCT02215148 Terminated - Brain Injury Clinical Trials

Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients

Start date: November 2014
Phase: N/A
Study type: Observational

To assess the pharmacokinetic profile of tolvaptan in critically ill acute brain injury patients and to secondarily evaluate the clinical response and safety of tolvaptan in acute brain injured patients

NCT ID: NCT02020278 Terminated - Hyponatremia Clinical Trials

An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia

Start date: April 22, 2016
Phase: Phase 3
Study type: Interventional

The objective of this trial was to provide 6 months of safety follow-up for children and adolescents with dilutional (euvolemic or hypervolemic) hyponatremia who had previously participated in a tolvaptan hyponatremia trial and to assess the efficacy of tolvaptan in increasing serum sodium for those participants who received optional continuing tolvaptan treatment of variable duration (up to 6 months).

NCT ID: NCT02012959 Terminated - Hyponatremia Clinical Trials

Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia

Start date: September 22, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this trial was to demonstrate that tolvaptan effectively and safely increases and maintains serum sodium concentrations in children and adolescent participants with euvolemic or hypervolemic hyponatremia.

NCT ID: NCT01890694 Terminated - Hyponatremia Clinical Trials

Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

Start date: March 2012
Phase: Phase 4
Study type: Interventional

Hyponatremia is a condition in which there is a low sodium level in the blood. Individuals with cirrhosis may develop low blood sodium as a complication of their liver disease. In these patients, the presence of low blood sodium may exacerbate other complications such as encephalopathy, resulting in confusion, drowsiness, or coma. It may also affect the ability of the body to fight infection. In certain cases, cirrhotic patients may be hospitalized for the treatment of their low blood sodium. The drug tolvaptan is currently FDA approved for the treatment of hyponatremia in patients with cirrhosis. Although it has been shown to increase the sodium level, the clinical trials that led to its approval did not otherwise assess clinical benefit of the drug. This study is designed to determine whether patients with cirrhosis derive a clinical benefit when they receive tolvaptan for the treatment of hyponatremia within 2 days of admission. Specifically, whether it is associated with shortened length of stay and improvement in other complications of cirrhosis.